Three clinical-stage biopharmaceutical companies moved to go public this week, filing amended S-1 registration statements with the Securities and Exchange Commission covering a cardiovascular drug, an immune-disease biologics platform, and a metabolic disease program.

Braveheart Bio files for IPO

Braveheart Bio, Inc. is offering 18,750,000 shares of common stock in its initial public offering, with a price range of $15.00 to $17.00 per share.¹ The company applied to list on the Nasdaq Global Market under the symbol "BRVE" and has granted underwriters an option to purchase up to 2,812,500 additional shares.¹ Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor are serving as joint bookrunners. Fidelity Management & Research Company has indicated non-binding interest in purchasing up to $75 million in shares as a cornerstone investor.

Braveheart is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. Its lead candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for obstructive HCM and non-obstructive HCM.¹ The compound was originally discovered by Jiangsu Hengrui Pharmaceuticals in China, and Braveheart in-licensed worldwide rights excluding Greater China in September 2025. All clinical trials completed to date, including a Phase I study conducted in Australia, were designed, sponsored and conducted by Hengrui.¹

Attovia Therapeutics files for IPO backing immune-disease pipeline

In it’s public offering, Attovia Therapeutics, Inc. is offering 12,500,000 shares of common stock at an estimated price range of $15.00 to $17.00 per share, with plans to list on the Nasdaq Global Market under the symbol "ATTO."² Underwriters have a 30-day option to purchase up to 1,875,000 additional shares, with Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital underwriting the offering.² Attovia estimates net proceeds of approximately $182.4 million based on the midpoint of the range.

Attovia is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its Attobody biologics platform, in-licensed from Alamar Biosciences.² The platform uses an evolution-driven, high-throughput process to discover biparatopic and multispecific biologics. Attovia's lead candidate, ATTO-1310, targets interleukin-31 and completed dosing in a Phase I clinical trial in healthy volunteers and patients with chronic pruritus and high-itch atopic dermatitis in the first quarter of 2026. Initial data from a Phase IB portion of the trial showed rapid, deep itch relief in both patient populations. The company plans to initiate a Phase II trial for ATTO-1310 by the first half of 2027.²

Founded in 2023, Attovia has raised $255.8 million from investors including Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives and venBio. As of June 30, 2026, the company estimated approximately $115.1 million in cash, cash equivalents and marketable securities.²

Vogenx files for IPO to fund mizagliflozin development

Finally, Vogenx, Inc. is offering 6,250,000 shares of common stock at an estimated price of $11.00 to $13.00 per share, with plans to list on the Nasdaq Capital Market under the symbol "VOGX."³ Jones is serving as sole book-running manager, giving underwriters a 45-day option to purchase up to 937,500 additional shares. Vogenx estimates net proceeds of approximately $67.8 million based on an assumed offering price of $12.00 per share.³

Vogenx is a clinical-stage biopharmaceutical company focused on disorders linked to human metabolism, including post-bariatric hypoglycemia and gastroparesis. Its lead candidate, mizagliflozin, is an orally administered, minimally absorbed inhibitor of the sodium-glucose transporter 1 (SGLT1), discovered by Kissei Pharmaceutical and licensed worldwide by Vogenx outside Japan, Korea and Taiwan in 2021.³ Mizagliflozin has been administered to more than 500 subjects across ten clinical studies to date.

Founded in 2021, Vogenx has raised approximately $11.5 million since inception. The company is led by chairman, president and chief executive officer James Green, who previously served as chief executive officer at Avolynt and BHV Pharma.³

Sources

1. Amendment No. 1 To Form S-1 Braveheart Bio .United States Securities and Exchange Commission July 30, 2026 https://www.sec.gov/Archives/edgar/data/2131524/000162828026050756/braveheartbioinc-sx1a.htm
2. Amendment No. 1 To Form S-1 Attovia Therapeutics United States Securities and Exchange Commission July 29, 2026 https://www.sec.gov/Archives/edgar/data/2058707/000119312526323618/d40469ds1a.htm
3. Amendment No. 1 To Form S-1Vogenx Inc. United States Securities and Exchange Commission July 29, 2026 https://www.sec.gov/Archives/edgar/data/1903784/000118518526003162/vogenxs1a1072526.htm